Study detail
RecruitingPhase 3
Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaukos Corporation
Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Description
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Interventions
- DrugGen 2 Travoprost Intracameral Implant
Travoprost
- DrugTimolol eye drops 0.5%
Timolol 0.5%
- ProcedureSham Procedure
Sham implant administration
- Otherplacebo eye drops
Artificial Tears
Location
- Glaukos Investigative SiteDothan, Alabama